NYU Langone Health and the NYU Grossman School of Medicine New York NY.
J Am Heart Assoc. 2024 Oct 15;13(20):e036921. doi: 10.1161/JAHA.124.036921. Epub 2024 Oct 11.
Genetic testing is a cornerstone in the assessment of many cardiac diseases. However, variants are frequently classified as variants of unknown significance, limiting the utility of testing. Recently, the DeepMind group (Google) developed AlphaMissense, a unique artificial intelligence-based model, based on language model principles, for the prediction of missense variant pathogenicity. We aimed to report on the performance of AlphaMissense, accessed by VarCardio, an open web-based variant annotation engine, in a real-world cardiovascular genetics center.
All genetic variants from an inherited arrhythmia program were examined using AlphaMissense via VarCard.io and compared with the ClinVar variant classification system, as well as another variant classification platform (Franklin by Genoox). The mutation reclassification rate and genotype-phenotype concordance were examined for all variants in the study. We included 266 patients with heritable cardiac diseases, harboring 339 missense variants. Of those, 230 (67.8%) were classified by ClinVar as either variants of unknown significance or nonclassified. Using VarCard.io, 198 variants of unknown significance (86.1%, 95% CI, 80.9-90.3) were reclassified to either likely pathogenic or likely benign. The reclassification rate was significantly higher for VarCard.io than for Franklin (86.1% versus 34.8%, <0.001). Genotype-phenotype concordance was highly aligned using VarCard.io predictions, at 95.9% (95% CI, 92.8-97.9) concordance rate. For 109 variants classified as pathogenic, likely pathogenic, benign, or likely benign by ClinVar, concordance with VarCard.io was high (90.5%).
AlphaMissense, accessed via VarCard.io, may be a highly efficient tool for cardiac genetic variant interpretation. The engine's notable performance in assessing variants that are classified as variants of unknown significance in ClinVar demonstrates its potential to enhance cardiac genetic testing.
基因检测是评估许多心脏疾病的基石。然而,变体通常被归类为意义不明的变体,限制了检测的实用性。最近,DeepMind 组(谷歌)基于语言模型原理,开发了一种独特的人工智能模型 AlphaMissense,用于预测错义变体的致病性。我们旨在报告通过 VarCardio 访问的 AlphaMissense 的性能,VarCardio 是一种基于网络的开放变体注释引擎,用于在真实的心血管遗传学中心。
通过 VarCard.io 使用 AlphaMissense 检查了遗传性心律失常计划的所有遗传变体,并将其与 ClinVar 变体分类系统以及另一个变体分类平台(Genoox 的 Franklin)进行了比较。研究中所有变体的突变再分类率和基因型-表型一致性均进行了检查。我们纳入了 266 名患有遗传性心脏病的患者,携带 339 种错义变体。其中,230 种(67.8%)根据 ClinVar 被归类为意义不明或未分类的变体。使用 VarCard.io,198 种意义不明的变体(86.1%,95%CI,80.9-90.3)被重新分类为可能致病性或可能良性。VarCard.io 的再分类率明显高于 Franklin(86.1%比 34.8%,<0.001)。使用 VarCard.io 预测的基因型-表型一致性非常一致,为 95.9%(95%CI,92.8-97.9)。对于 ClinVar 分类为致病性、可能致病性、良性或可能良性的 109 种变体,与 VarCard.io 的一致性很高(90.5%)。
通过 VarCard.io 访问的 AlphaMissense 可能是一种用于心脏遗传变异解释的高效工具。该引擎在评估 ClinVar 中归类为意义不明的变体方面的出色表现表明,它有可能增强心脏遗传检测。